JNJ250502P172500
- 13.37
- 0.000.00%
Johnson & Johnson Newsroom
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $170
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Johnson & Johnson Retains 'AAA' Rating at S&P, Credit Outlook Stable
TD Cowen Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $185
HSBC Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $184
Will the US Stock Market's Rebound Ignite Your Next Trade?
Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival
Express News | Johnson & Johnson : HSBC Raises Target Price to $184 From $180
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems 'Behind It'
J&J Posts Mid-stage Trial Data for Chemotherapy Releasing System in Bladder Cancer
Express News | Johnson & Johnson - Initiates FDA Application for Tar-200 Under Rtor Program
Express News | Johnson & Johnson - Phase 2B Study: 82% Achieve Complete Response, 52.9% Cancer-Free at One Year
Express News | Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits in Patients With Certain Types of Bladder Cancer
Johnson & Johnson's TAR-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits in Patients With Certain Types of Bladder Cancer
Is Johnson & Johnson (JNJ) the Best Safe Stock to Buy According to Hedge Funds?
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Johnson & Johnson (JNJ.US) has a stable financial condition, and S&P has removed the downgrade warning.
S&P has removed Johnson & Johnson from the downgrade watch list, citing the company's "very conservative financial policy."
Market Chatter: Third Point Capital Builds Stake in Kenvue
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports